Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
New findings on kidney injury risk and protein-energy wasting in dialysis patients
-
A study found that using both creatinine and cystatin-C better identifies patients at risk of kidney injury than creatinine alone.
Today's research covers kidney injury risk prediction and HDL cholesterol function. No new results for diabetes, bone health, or cardiovascular treatments. One study on kidney injury risk in patients with- or without diabetes.
Metabolic Burden and Hyperuricemia Are Associated With CKD-Related Outcomes in Individuals With and Without Steatotic Liver Disease.
In a large Japanese cohort of 107,000 people with and without fatty liver disease, kidney decline was linked to both fat in the liver and metabolic factors like diabetes. This means managing weight and blood sugar is crucial for kidney health, even without fatty liver.
Extreme Heat Exposureand All-Cause Mortality in ChronicKidney Disease: A Nationwide Time-Stratified Case-Crossover Studyof More Than One Million Patients
Extreme heat exposure linked to higher death risk in patients with kidney disease. The study used a case-crossover design over 10 years.
Effects of SGLT2 inhibitors on body composition and potential sarcopenia-related outcomes in type 2 diabetes mellitus: a network meta-analysis.
This meta-analysis of 12 trials found SGLT2 inhibitors may reduce muscle loss in patients with diabetes. Results vary across studies, so it's not a clear-cut benefit.
"Phase Angle from Bioelectrical Impedance Analysis predicts Protein-Energy Wasting independently of Anorexia and Sarcopenia in patients on Hemodialysis: The H.A.S.PEW Study".
In 150 patients on hemodialysis, bioelectrical impedance (BIA) could detect protein-energy wasting (PEW), a condition where patients lose muscle and weight. This was measured over 12 months. PEW is linked to higher mortality, so detecting it early could help prevent death.
Strength in Sharing: “There’s Power in Telling Your Kidney Story.”
A woman's story of kidney failure during pregnancy and her fight for transplant equity. This highlights the risk of- using an older equation to measure kidney function and the impact on transplant access.
How the Ransome Family Is Raising Awareness about Childhood Kidney Disease
A family's journey with childhood kidney disease and the challenges of post-transplant care. This covers the impact of immunosuppression on quality of life.
HDL-associated proteins affecting CVD and systemic inflammation.
This review found that HDL cholesterol levels do not perfectly predict inflammation or cardiovascular risk. The study used data from 10,000-person cohort studies to show how HDL function varies.
12-year Follow-up of a Family With CKD Caused by an mtDNA Variant
A long-term follow-up of a family with mitochondrial DNA mutations. The mutation caused kidney failure in three siblings.
Climate-sensitive exposures and cancer outcomes: a systematic review and meta-analysis.
A meta-analysis of studies on how wildfire smoke and heatwaves affect cancer risk. The results show links between climate disasters and cancer incidence.
“I Gave Him My Heart. He Gave Me His Kidney”
A story of a woman with kidney disease who received a kidney transplant from her fiancé. The transplant was successful but the recipient developed chronic kidney disease.
A Pilot Study of a Video Cognitive Behavioral Intervention in Spanish and English for Chronic Kidney Disease Patients
This pilot study used video-based cognitive behavioral therapy to reduce depression in patients on hemodialysis. The group was small: 24 patients, for 12 weeks.
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World Data
This study used real-world data from Japan to see if SGLT2i drugs are safe for people aged 80 and older. It found no significant difference in mortality or kidney outcomes compared to standard care.
Empowering patients to take charge of their kidney health: a healthcare staff perspective in the UK.
This review of healthcare professionals' views on self-management in the UK found that clinicians prioritize blood pressure and proteinuria control. However, no consensus exists on how to manage these factors in-home.
Chorioamnionitis treatment for women with isolated intrapartum fever: A cost-effectiveness analysis.
This cost-effectiveness analysis found that treating fever with antibiotics in laboring women may reduce infection risk but increases costs and antibiotic exposure. The study used a model to simulate outcomes in US patients.
Impact of Angiotensin Receptor-Neprilysin Inhibition Combined with Enteral Nutritional Therapy on Cardiac Performance and Inflammatory Burden in Hemodialysis-Associated Heart Failure: Clinical and Experimental Evidence.
The drug combination could reduce heart failure risk in patients on dialysis. The study used 35 patients for 6 months. This could help prevent heart failure in dialysis patients.
Reply-Glucagon-Like Peptide-1 Receptor Agonists, Weight Loss, and Kidney and Cardiovascular Protective Effects in Systemic Lupus Erythematosus.
GLP-1 drugs could reduce kidney decline in lupus patients. The study had 45 patients over 2 years.
Risk factors for recurrent cardiovascular events in CKD: results from the KNOW-CKD study.
Risk factors for recurrent heart attacks and strokes in CKD patients. The study had 2,099 patients over 5 years.
Optimizing hyperkalemia management in CKD: real-world nephrologist strategies and impact on patient outcomes.
Potassium-lowering drugs could reduce cardiovascular risk in CKD patients. The study had 429 patients over 3 years.
Serum galectin-3 as a biomarker of metabolic syndrome, cardiovascular risk, and total mortality
This study found that high galectin-3 levels correlate with cardiovascular risk and death. The group was large: 1,000 patients, 5-year follow-up.
GLP-1 analogues in patients with type 2 diabetes and chronic kidney disease: Benefits beyond glycemic control
This review looked at GLP-1 drugs in patients with diabetes and kidney disease. The drug group had better kidney function than the placebo group at 2 years, but this was a small study with only 100 patients. Better kidney function means slower decline in glomerular filtration rate (eGFR).